MCID: BRN028
MIFTS: 74

Brain Cancer

Categories: Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Brain Cancer

MalaCards integrated aliases for Brain Cancer:

Name: Brain Cancer 12 54 15
Malignant Neoplasm of Brain 29 71 32
Adult Brain Tumor 12 54 71
Brain Neoplasms 74 43 71
Primary Malignant Neoplasm of Brain 12 71
Neoplasm of Brain 12 6
Brain Neoplasm 12 17
Brain Tumors 54 42
Malignant Primary Brain Neoplasm 12
Adult Malignant Brain Neoplasm 12
Malignant Tumor of Adult Brain 12
Malignant Primary Brain Tumors 54
Malignant Primary Brain Tumor 12
Malignant Tumor of Brain 12
Malignant Brain Tumour 12
Primary Brain Neoplasm 12
Brain Neoplasm, Adult 12
Primary Brain Tumors 15
Brain Tumor, Primary 71
Primary Brain Tumor 12
Brain Tumor Primary 54
Tumor of the Brain 12
Brain Tumor, Adult 52
Bt - Brain Tumour 12
Cancer, Brain 39

Classifications:



External Ids:

Disease Ontology 12 DOID:1319
ICD9CM 34 191 191.9 239.6
MeSH 43 D001932
SNOMED-CT 67 93727008
ICD10 32 C71 C71.9
UMLS 71 C0006118 C0153633 C0220624 more

Summaries for Brain Cancer

MedlinePlus : 42 A brain tumor is a growth of abnormal cells in the tissues of the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Some are primary brain tumors, which start in the brain. Others are metastatic, and they start somewhere else in the body and move to the brain. Brain tumors can cause many symptoms. Some of the most common are Headaches, often in the morning Nausea and vomiting Changes in your ability to talk, hear, or see Problems with balance or walking Problems with thinking or memory Feeling weak or sleepy Changes in your mood or behavior Seizures Doctors diagnose brain tumors by doing a neurologic exam and tests including an MRI, CT scan, and biopsy. Treatment options include watchful waiting, surgery, radiation therapy, chemotherapy, and targeted therapy. Targeted therapy uses drugs or other substances that attack cancer cells with less harm to normal cells. Many people get a combination of treatments. NIH: National Cancer Institute

MalaCards based summary : Brain Cancer, also known as malignant neoplasm of brain, is related to li-fraumeni syndrome and medulloblastoma, and has symptoms including seizures, tremor and back pain. An important gene associated with Brain Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are TGF-Beta Pathway and Regulation of lipid metabolism Insulin signaling-generic cascades. The drugs Tramadol and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.

Wikipedia : 74 A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors:... more...

Related Diseases for Brain Cancer

Diseases related to Brain Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1143)
# Related Disease Score Top Affiliating Genes
1 li-fraumeni syndrome 34.0 TP53 PTEN IDH1 EGFR
2 medulloblastoma 33.6 TP53 SMARCB1 PTPN11 PTEN PIK3CA NRAS
3 brain glioma 33.5 TP53 NES MGMT IDH2 IDH1 EGFR
4 infratentorial cancer 33.1 TP53 SMARCB1 PTEN OLIG2 NES MIR25
5 supratentorial cancer 33.1 TP53 SMARCB1 OLIG2 NES MGMT IDH2
6 spinal cancer 33.0 SMARCB1 NES IDH1
7 gliomatosis cerebri 33.0 TP53 PTEN NES IDH1 EGFR BRAF
8 cowden syndrome 32.8 TP53 PTEN PIK3CA EGFR
9 atypical teratoid rhabdoid tumor 32.7 TP53 SMARCB1 MIR142 ALK
10 glioblastoma multiforme 32.7 TP53 PTEN PIK3CA NRAS NES MGMT
11 glial tumor 32.3 PTEN OLIG2 IDH1
12 glioma 32.3 TP53 PTEN PIK3CA MIR25 IDH2 IDH1
13 cerebral ventricle cancer 31.9 TP53 SMARCB1 OLIG2 NES MGMT IDH2
14 giant cell glioblastoma 31.9 TP53 PTEN OLIG2 MGMT IDH2 IDH1
15 central nervous system benign neoplasm 31.9 TP53 PTEN OLIG2 IDH2 IDH1
16 meningioma, familial 31.8 TP53 SMARCB1 PTEN OLIG2 MGMT IDH1
17 oligodendroglioma 31.8 TP53 PTEN OLIG2 MGMT IDH2 IDH1
18 gemistocytic astrocytoma 31.8 TP53 PTEN MGMT IDH2 IDH1
19 pleomorphic xanthoastrocytoma 31.7 TP53 SMARCB1 MGMT IDH2 IDH1 BRAF
20 frontal lobe neoplasm 31.7 TP53 MGMT IDH1 EGFR
21 cerebellum cancer 31.7 TP53 IDH2 IDH1
22 astroblastoma 31.7 NES IDH1 BRAF
23 cerebellar astrocytoma 31.6 IDH2 IDH1 BRAF
24 malignant glioma 31.6 TP53 PTEN MGMT EGFR
25 neuroblastoma 31.5 TP53 PTPN11 PTEN PIK3CA NRAS NES
26 central nervous system cancer 31.5 TP53 SMARCB1 PTEN OLIG2 NES MIR25
27 colorectal cancer 31.5 TP53 PTEN PIK3CA NRAS MIR25 MIR142
28 carcinosarcoma 31.4 TP53 PTEN PIK3CA EGFR
29 small cell carcinoma 31.4 TP53 PTEN EGFR ALK
30 grade iii astrocytoma 31.4 TP53 PTEN OLIG2 NES MGMT IDH2
31 intrahepatic cholangiocarcinoma 31.3 TP53 PTEN IDH2 IDH1 EGFR
32 myelodysplastic syndrome 31.3 TP53 PTPN11 PTEN NRAS MGMT IDH2
33 transitional cell carcinoma 31.3 TP53 PTEN EPHB2 EGFR BRAF
34 cholangiocarcinoma 31.3 TP53 PTEN PIK3CA IDH2 IDH1 EGFR
35 nervous system cancer 31.3 TP53 PTEN MIR25 MIR142 MGMT IDH1
36 fibrillary astrocytoma 31.3 TP53 PTEN OLIG2 MGMT IDH2 IDH1
37 brain stem glioma 31.3 TP53 PTEN PIK3CA OLIG2 NES MGMT
38 myeloma, multiple 31.3 TP53 PTPN11 PTEN NRAS MIR25 MIR142
39 neurofibroma 31.3 TP53 PTEN EGFR
40 temporal lobe neoplasm 31.2 MGMT IDH1
41 hydrocephalus 31.2 TP53 SMARCB1 PTEN NRAS NES
42 juvenile pilocytic astrocytoma 31.2 PTEN OLIG2 NES MGMT IDH1
43 anaplastic oligodendroglioma 31.2 OLIG2 MGMT IDH2
44 endometrial cancer 31.2 TP53 PTPN11 PTEN PIK3CA NRAS EGFR
45 mixed glioma 31.2 TP53 PTEN OLIG2 NES MGMT IDH2
46 ganglioglioma 31.1 TP53 SMARCB1 NES BRAF
47 gliosarcoma 31.1 TP53 PTEN OLIG2 NES MGMT IDH2
48 tuberous sclerosis 31.1 TP53 PTEN PIK3CA NES
49 benign ependymoma 31.1 NES MGMT EGFR
50 basal cell carcinoma 31.1 TP53 PTEN EPHB2 EGFR BMI1

Comorbidity relations with Brain Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Brain Edema
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Hypertension, Essential
Obstructive Hydrocephalus Schizophreniform Disorder

Graphical network of the top 20 diseases related to Brain Cancer:



Diseases related to Brain Cancer

Symptoms & Phenotypes for Brain Cancer

UMLS symptoms related to Brain Cancer:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Brain Cancer according to GeneCards Suite gene sharing:

26 (show top 50) (show all 63)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.7 BRAF
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.7 BMI1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.7 EGFR PTPN11
4 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.7 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.7 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.7 EGFR PTPN11
7 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.7 NES
8 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.7 TP53
9 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.7 PTPN11
10 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.7 NES
11 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.7 BRAF PTPN11
12 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.7 PTEN
13 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.7 PTEN
14 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.7 PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.7 BIRC6 IDH2 PIK3CA NES PTEN
16 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.7 BRAF PIK3CA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.7 PTEN
18 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.7 TP53
19 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.7 NES
20 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.7 IDH2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.7 BIRC6 BMI1 BRAF IDH2 PIK3CA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.7 PTPN11
23 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.7 NES
24 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.7 TP53
25 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.7 BMI1 PIK3CA EGFR PTPN11 TP53
26 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.7 BRAF
27 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.7 NES
28 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.7 IDH2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.7 BIRC6
30 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.7 NES
31 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.7 EGFR
32 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.7 PTEN EGFR
33 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.7 BIRC6
34 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.7 BRAF
35 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.7 BMI1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.7 BRAF
37 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.7 BRAF
38 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.7 TP53
39 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.7 PTPN11
40 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.7 TP53
41 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.7 BIRC6 IDH2 PIK3CA PTEN
42 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.7 EGFR
43 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.7 BRAF PTPN11
44 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.7 PIK3CA
45 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.7 PIK3CA
46 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.7 BMI1 PTEN
47 Increased shRNA abundance (Z-score > 2) GR00366-A-69 10.7 IDH2
48 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.7 PTPN11
49 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.7 IDH2
50 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.7 BIRC6

MGI Mouse Phenotypes related to Brain Cancer:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.34 ALK BIRC6 BRAF EGFR EPHB2 IDH1
2 cellular MP:0005384 10.31 BIRC6 BRAF EGFR EPHB2 NRAS OLIG2
3 mortality/aging MP:0010768 10.3 ALK BIRC6 BRAF EGFR EPHB2 IDH1
4 endocrine/exocrine gland MP:0005379 10.28 ALK BIRC6 BRAF EGFR EPHB2 MGMT
5 cardiovascular system MP:0005385 10.27 BIRC6 BRAF EGFR IDH2 NRAS PIK3CA
6 integument MP:0010771 10.21 ALK BIRC6 BRAF EGFR NRAS PIK3CA
7 embryo MP:0005380 10.2 BIRC6 BRAF EGFR NRAS PIK3CA PTEN
8 neoplasm MP:0002006 10.18 ALK BRAF EGFR IDH2 MGMT NRAS
9 digestive/alimentary MP:0005381 10.16 BRAF EGFR EPHB2 NRAS PTEN PTPN11
10 nervous system MP:0003631 10.15 ALK BIRC6 BRAF EGFR EPHB2 MGMT
11 adipose tissue MP:0005375 10.13 BRAF EGFR OLIG2 PIK3CA PTEN PTPN11
12 liver/biliary system MP:0005370 10.08 BIRC6 BRAF EGFR NRAS PTEN PTPN11
13 limbs/digits/tail MP:0005371 10.04 BRAF EGFR IDH2 NRAS PTEN PTPN11
14 muscle MP:0005369 10.03 BRAF EGFR OLIG2 PIK3CA PTEN PTPN11
15 no phenotypic analysis MP:0003012 9.87 EGFR MGMT NRAS OLIG2 PIK3CA PTPN11
16 respiratory system MP:0005388 9.81 ALK BRAF EGFR IDH1 MGMT OLIG2
17 pigmentation MP:0001186 9.8 ALK BRAF EGFR NRAS PTEN PTPN11
18 skeleton MP:0005390 9.7 ALK BRAF EGFR IDH1 IDH2 NRAS
19 vision/eye MP:0005391 9.36 ALK BRAF EGFR EPHB2 NRAS OLIG2

Drugs & Therapeutics for Brain Cancer

Drugs for Brain Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 666)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
2
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Octreotide Approved, Investigational Phase 4 83150-76-9 6400441 383414
5
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
6
Ephedrine Approved Phase 4 299-42-3 9294
7
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
8
Phenylephrine Approved Phase 4 59-42-7 6041
9
Pseudoephedrine Approved Phase 4 90-82-4 7028
10
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
11
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
12
Somatostatin Approved, Investigational Phase 4 51110-01-1, 38916-34-6 53481605
13
Cabergoline Approved Phase 4 81409-90-7 54746
14
Labetalol Approved Phase 4 36894-69-6 3869
15
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
16
Clevidipine Approved, Investigational Phase 4 167221-71-8
17
Hydralazine Approved Phase 4 86-54-4 3637
18
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
19
Memantine Approved, Investigational Phase 4 19982-08-2 4054
20
Donepezil Approved Phase 4 120014-06-4 3152
21
Propranolol Approved, Investigational Phase 4 525-66-6 4946
22
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
23
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
24
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
25
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
26
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
27 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
28
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
29
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
30
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
31
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
32
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
33
Amitriptyline Approved Phase 4 50-48-6 2160
34
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
35
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
36
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
37
Racepinephrine Approved Phase 4 329-65-7 838
38
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
39
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
40
Conivaptan Approved, Investigational Phase 4 210101-16-9 151171
41
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
42
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
43 calcium channel blockers Phase 4
44 Central Nervous System Stimulants Phase 4
45 Dopamine Uptake Inhibitors Phase 4
46 Cytochrome P-450 CYP3A Inhibitors Phase 4
47 Cytochrome P-450 Enzyme Inhibitors Phase 4
48 Antiparkinson Agents Phase 4
49 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Phase 4
50 Antihypertensive Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1715)
# Name Status NCT ID Phase Drugs
1 Effect of Single Dose of Tramadol on Extubation Response and Quality of Emergence(Cough and Nausea Vomiting) Following Supratentorial Intracranial Surgery Unknown status NCT02964416 Phase 4 Injection Tramadol
2 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
3 Use of Integrated PET/MR to Evaluate Clinical Staging and Monitor Treatment Response of Neoadjuvant Chemotherapy for Breast Cancer Patients: A Pilot Study Unknown status NCT02766530 Phase 4
4 Prospective Trial of Intravenous Levetiracetam in Patients With Primary Brain Tumors and at Least One Symptomatic Seizure Who Undergo Biopsy or Cytoreductive Surgery (HELLO-study) Completed NCT00571155 Phase 4 levetiracetam
5 Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
6 Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
7 A Prospective, Randomized Trial Comparing Surgery Versus Radiosurgery for the Treatment of Metastatic Brain Tumors Completed NCT00075166 Phase 4
8 Sugammadex Given for the Reversal of Deep Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants: A Retrospective Study Completed NCT02708056 Phase 4 Sugammadex
9 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
10 A Randomized, Open Label, Two-way Crossover, Single Dose Bioequivalence Study Comparing Dralitem® Capsules to the Reference Drug Temodal® Capsules in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
11 Influence of Vasopressors on Brain Oxygenation and Microcirculation in Anesthetized Patients With Cerebral Tumors Completed NCT02713087 Phase 4 Ephedrine;Phenylephrine
12 Phase IV, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare 0.10 Mmol/kg of MultiHance With 0.10 Omniscan in Magnetic Resonance Imaging (MRI) of the Brain Completed NCT00323102 Phase 4 Multihance
13 A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
14 A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
15 Phase IV, Double-blind, Multi-center, Randomized, Crossover Study to Compare 0.1 mmol/kg of Prohance® With 0.1 mmol/kg of Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain (TRUTH) Completed NCT01613417 Phase 4 gadoteridol;gadobutrol
16 The Effect of Pre-incisional Anterior Scalp Block on Intraoperative Opioid Consumption in Adult Patients Undergoing Elective Craniotomy to Remove Tumor: A Prospective Randomized Controlled Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
17 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
18 The Effect of Dexmedetomidine as an Adjuvant to General Anesthesia on Intelligence Development in Pediatric Patients Undergoing Craniotomy: a Randomized, Double-blind and Placebo-controlled Pilot Trial Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
19 The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block: A Randomized Controlled Trial Completed NCT02558569 Phase 4 Levobupivacaine
20 The Effect of Intravenous Single Dose of Magnesium Sulphate on Attenuation of Hemodynamic Pressor Response After Myfield's Clamp Application During Craniotomies Completed NCT03318471 Phase 4 MgSo4;0.9% NaCl
21 Validation and Verification of 3 Dimensional Laparoscopic System in Laparoscopic Distal Pancreatectomy & Splenectomy Completed NCT02757690 Phase 4
22 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
23 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
24 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
25 A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial Recruiting NCT02334722 Phase 4 Levetiracetam extended release
26 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
27 Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
28 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
29 GCSF Plus Plerixafor as First-line Treatment for Autologous Stem Cells Harvest in Children With Malignant Diseases in Need for High-dose Chemotherapy With Stem Cell Rescue. Not yet recruiting NCT02006225 Phase 4 Plerixafor
30 Effects of Pre-emptive Scalp Infiltration With Ketorolac and Ropivacaine for Postoperative Pain Relief After Elective Supratentorial Craniotomy (PAINLESS) Not yet recruiting NCT04141319 Phase 4 Ketorolac;Ropivacaine;Epinephrine
31 Phase IV GliaSite® Radiation Therapy System Registry Protocol for the Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
32 Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients Terminated NCT00727090 Phase 4 Conivaptan
33 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Terminated NCT02028325 Phase 4 Fluorescein Sodium
34 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
35 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
36 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
37 Role of 3-D Navigable Ultrasound in Resection of Intra-axial Brain Tumors - A Randomized Controlled Study Unknown status NCT02150564 Phase 3
38 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
39 Barrow 5-ALA Intraoperative Confocal Evaluation Trial Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
40 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
41 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
42 Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients With and Without Traumatic Brain Injury. Unknown status NCT03285165 Phase 2, Phase 3 0.2-0.7 mcg/kg/h dexmedetomedine infusion.;10-70 mcg/kg/h propofol infusion.
43 Comparison of Esmolol and Dexmedetomidine on Sympathetic Control During Intracranial Procedures Unknown status NCT02563288 Phase 3 Esmolol;Dexmedetomidine
44 Gefitinib Alone or With Concomitant Whole Brain Radiotherapy for Patients Harboring an EGFR Mutation With Multiple Brain Metastases From Non-Small-cell Lung Cancer: a Phase II/III Randomized Controlled Trial Unknown status NCT02338011 Phase 2, Phase 3 Gefitinib
45 Phase 3 Study of Stereotactic Radiotherapy of the Postoperative Resection Cavity Versus Whole-Brain Irradiation After Surgical Resection of Single Brain Metastasis Unknown status NCT01535209 Phase 3
46 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Effective on Erlotinib or Gefitinib(RT1001) Unknown status NCT01158170 Phase 3 Erlotinib /Gefitinib
47 A Randomized Trial of Robotic Compared to Fixed Gantry Radiosurgery for Brain Metastases Unknown status NCT01353573 Phase 3
48 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
49 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
50 Intra-individual Comparison Study of Intravenously Administered Magnevist (SH L 451A) on Lesion Detection Ability in MRI After an Initial Dose of 0.1 mmol/kg and After an Additional Dose of 0.1 mmol/kg in Patients With Metastatic Brain Tumor Completed NCT00681551 Phase 3 Magnevist (SH L 451A);Magnevist (SH L 451A)

Search NIH Clinical Center for Brain Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine
Etoposide
etoposide phosphate
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Lomustine
Mifepristone
peginterferon alfa-2a
peginterferon alfa-2b
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Cochrane evidence based reviews: brain neoplasms

Genetic Tests for Brain Cancer

Genetic tests related to Brain Cancer:

# Genetic test Affiliating Genes
1 Malignant Neoplasm of Brain 29

Anatomical Context for Brain Cancer

MalaCards organs/tissues related to Brain Cancer:

40
Brain, Breast, Lung, T Cells, Testes, Endothelial, Bone

Publications for Brain Cancer

Articles related to Brain Cancer:

(show top 50) (show all 3638)
# Title Authors PMID Year
1
Prediction of relapse and prognosis by expression levels of long noncoding RNA PEG10 in glioma patients. 42
31702614 2019
2
The prognostic analysis of different metastatic patterns in pancreatic neuroendocrine tumors patients: A population based analysis. 42
31689842 2019
3
Histogram analysis of absolute cerebral blood volume map can distinguish glioblastoma from solitary brain metastasis. 42
31626111 2019
4
Survey of MicroRNA expression in pediatric brain tumors. 46
21157891 2011
5
FasL gene knock-down therapy enhances the antiglioma immune response. 61 54
20406899 2010
6
Mig-6 controls EGFR trafficking and suppresses gliomagenesis. 54 61
20351267 2010
7
MRI-coupled fluorescence tomography quantifies EGFR activity in brain tumors. 61 54
20152724 2010
8
CMDS: a population-based method for identifying recurrent DNA copy number aberrations in cancer from high-resolution data. 61 54
20031968 2010
9
A review of studies on targeting interleukin 4 receptor for central nervous system malignancy. 61 54
19689300 2009
10
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. 61 54
19333229 2009
11
Therapeutic targeting of g-protein coupled receptor-mediated epidermal growth factor receptor transactivation in human glioma brain tumors. 54 61
18991757 2008
12
Somatic alterations in brain tumors. 61 54
18575738 2008
13
Gene expression profiling of metastatic brain cancer. 61 54
17611651 2007
14
Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. 54 61
17483310 2007
15
Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. 61 54
17679463 2007
16
Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. 54 61
17440072 2007
17
Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. 54 61
17172420 2006
18
New roles for galectins in brain tumors--from prognostic markers to therapeutic targets. 54 61
15912884 2005
19
RNA interference and nonviral targeted gene therapy of experimental brain cancer. 54 61
15717065 2005
20
Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. 61 54
15173073 2004
21
Genetic polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the risk of adult brain tumors. 61 54
12540498 2003
22
Co-delivery of an antisense oligonucleotide and 5-fluorouracil using sustained release poly (lactide-co-glycolide) microsphere formulations for potential combination therapy in cancer. 54 61
11839444 2002
23
Ethnicity delineates different genetic pathways in malignant glioma. 54 61
11358811 2001
24
Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. 61 54
8700129 1996
25
Engineering HSV-1 Vectors for Gene Therapy. 61
31617173 2020
26
Nonviral polymeric nanoparticles for gene therapy in pediatric CNS malignancies. 61
31655205 2020
27
Model-Based High-Definition Dynamic Contrast Enhanced MRI for Concurrent Estimation of Perfusion and Microvascular Permeability. 61
31639623 2020
28
Palliative care utilization in hospitalized children with cancer. 61
31612605 2020
29
Native and iron-saturated bovine lactoferrin differently hinder migration in a model of human glioblastoma by reverting epithelial-to-mesenchymal transition-like process and inhibiting interleukin-6/STAT3 axis. 61
31678680 2020
30
Monte Carlo simulation of a 2D dynamic multileaf collimator to improve the plan quality in radiotherapy plan: a proof-of-concept study. 61
31726432 2019
31
New metabolic imaging tools in neuro-oncology. 61
31577603 2019
32
Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy. 61
31619389 2019
33
Truncated BRPF1 Cooperates with Smoothened to Promote Adult Shh Medulloblastoma. 61
31851932 2019
34
The long noncoding RNA TP73-AS1 promotes tumorigenicity of medulloblastoma cells. 61
31081944 2019
35
Lymphocytic ganglionitis leading to megacolon in lymphocyte-rich glioblastoma. 61
31655421 2019
36
Risk of primary brain tumour after breast cancer. 61
31821158 2019
37
Brain Cancer Triage Test Advances. 61
31821416 2019
38
The Role of ACKR3 in Breast, Lung, and Brain Cancer. 61
30745320 2019
39
Most Relevant Spectral Bands Identification for Brain Cancer Detection Using Hyperspectral Imaging. 61
31842410 2019
40
Bayesian Space-Time Analysis of Brain Cancer Incidence in Southern Ontario, Canada: 2010-2013. 61
31847406 2019
41
Racial differences in brain cancer characteristics and survival: an analysis of SEER data. 61
31641915 2019
42
Outcomes in Patients Treated with Laser Interstitial Thermal Therapy for Primary Brain Cancer and Brain Metastases. 61
31439811 2019
43
Knockdown of lncRNA LSINCT5 suppresses growth and metastasis of human glioma cells via up-regulating miR-451. 61
31213092 2019
44
Engineering, delivery, and biological validation of artificial microRNA clusters for gene therapy applications. 61
31748752 2019
45
CRISPR/Cas13a-Powered Electrochemical Microfluidic Biosensor for Nucleic Acid Amplification-Free miRNA Diagnostics. 61
31663165 2019
46
Coronarin D Induces Apoptotic Cell Death and Cell Cycle Arrest in Human Glioblastoma Cell Line. 61
31818017 2019
47
Health-related quality of life in adult patients with brain metastases after stereotactic radiosurgery: a systematic, narrative review. 61
31792879 2019
48
Dual-functional supramolecular nanohybrids of quantum dot/biopolymer/chemotherapeutic drug for bioimaging and killing brain cancer cells in vitro. 61
31542643 2019
49
Molecular imaging and advanced MRI findings following immunotherapy in patients with brain tumors. 61
31842635 2019
50
Computational modeling demonstrates that glioblastoma cells can survive spatial environmental challenges through exploratory adaptation. 61
31836713 2019

Variations for Brain Cancer

ClinVar genetic disease variations for Brain Cancer:

6 (show top 50) (show all 237) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53):c.832C>A (p.Pro278Thr)SNV Likely pathogenic,drug response 376643 rs17849781 17:7577106-7577106 17:7673788-7673788
2 TP53 NM_000546.5(TP53):c.537T>G (p.His179Gln)SNV Pathogenic 376607 rs876660821 17:7578393-7578393 17:7675075-7675075
3 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
4 TP53 NM_000546.5(TP53):c.517G>T (p.Val173Leu)SNV Pathogenic 376668 rs876660754 17:7578413-7578413 17:7675095-7675095
5 PTEN NM_000314.7(PTEN):c.388C>T (p.Arg130Ter)SNV Pathogenic 7819 rs121909224 10:89692904-89692904 10:87933147-87933147
6 PTEN NM_000314.7(PTEN):c.1003C>T (p.Arg335Ter)SNV Pathogenic 7833 rs121909231 10:89720852-89720852 10:87961095-87961095
7 TP53 NM_000546.5(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
8 TP53 NM_000546.5(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
9 TP53 NM_000546.5(TP53):c.734G>A (p.Gly245Asp)SNV Pathogenic 12355 rs121912656 17:7577547-7577547 17:7674229-7674229
10 TP53 NM_000546.5(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
11 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
12 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
13 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu)SNV Pathogenic 13961 rs113488022 7:140453136-140453136 7:140753336-140753336
14 BRAF NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly)SNV Pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354
15 TP53 NM_000546.5(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
16 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
17 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
18 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
19 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg)SNV Pathogenic 45466 rs397517201 3:178936095-178936095 3:179218307-179218307
20 TP53 NM_000546.5(TP53):c.488A>G (p.Tyr163Cys)SNV Pathogenic 127814 rs148924904 17:7578442-7578442 17:7675124-7675124
21 TP53 NM_000546.5(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
22 TP53 NM_000546.5(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
23 TP53 NM_000546.5(TP53):c.422G>A (p.Cys141Tyr)SNV Pathogenic 140801 rs587781288 17:7578508-7578508 17:7675190-7675190
24 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
25 TP53 NM_000546.5(TP53):c.706T>G (p.Tyr236Asp)SNV Pathogenic 142183 rs587782289 17:7577575-7577575 17:7674257-7674257
26 IDH1 NM_005896.3(IDH1):c.395G>A (p.Arg132His)SNV Pathogenic 156444 rs121913500 2:209113112-209113112 2:208248388-208248388
27 TP53 NM_000546.5(TP53):c.856G>A (p.Glu286Lys)SNV Pathogenic 183752 rs786201059 17:7577082-7577082 17:7673764-7673764
28 PTEN NM_000314.7(PTEN):c.517C>T (p.Arg173Cys)SNV Pathogenic 189500 rs121913293 10:89711899-89711899 10:87952142-87952142
29 TP53 NM_000546.5(TP53):c.584T>C (p.Ile195Thr)SNV Pathogenic 216077 rs760043106 17:7578265-7578265 17:7674947-7674947
30 TP53 NM_000546.5(TP53):c.833C>T (p.Pro278Leu)SNV Pathogenic 232497 rs876659802 17:7577105-7577105 17:7673787-7673787
31 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro)SNV Pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
32 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His)SNV Pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
33 TP53 NM_000546.5(TP53):c.712T>C (p.Cys238Arg)SNV Pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
34 TP53 NM_000546.5(TP53):c.713G>T (p.Cys238Phe)SNV Pathogenic 376574 rs730882005 17:7577568-7577568 17:7674250-7674250
35 TP53 NM_000546.5(TP53):c.809T>C (p.Phe270Ser)SNV Pathogenic/Likely pathogenic 376594 rs1057519986 17:7577129-7577129 17:7673811-7673811
36 PIK3CA NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln)SNV Pathogenic/Likely pathogenic 376244 rs121913273 3:178936082-178936082 3:179218294-179218294
37 TP53 NM_000546.5(TP53):c.731G>A (p.Gly244Asp)SNV Pathogenic/Likely pathogenic 372785 rs985033810 17:7577550-7577550 17:7674232-7674232
38 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu)SNV Pathogenic/Likely pathogenic 375874 rs11554290 1:115256529-115256529 1:114713908-114713908
39 IDH1 NM_005896.3(IDH1):c.395G>T (p.Arg132Leu)SNV Pathogenic/Likely pathogenic 375889 rs121913500 2:209113112-209113112 2:208248388-208248388
40 IDH1 NM_005896.3(IDH1):c.394C>T (p.Arg132Cys)SNV Pathogenic/Likely pathogenic 375891 rs121913499 2:209113113-209113113 2:208248389-208248389
41 IDH1 NM_005896.3(IDH1):c.394C>G (p.Arg132Gly)SNV Pathogenic/Likely pathogenic 375892 rs121913499 2:209113113-209113113 2:208248389-208248389
42 IDH1 NM_005896.3(IDH1):c.394C>A (p.Arg132Ser)SNV Pathogenic/Likely pathogenic 375893 rs121913499 2:209113113-209113113 2:208248389-208248389
43 PIK3CA NM_006218.4(PIK3CA):c.1637A>C (p.Gln546Pro)SNV Pathogenic/Likely pathogenic 375898 rs397517201 3:178936095-178936095 3:179218307-179218307
44 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)SNV Pathogenic/Likely pathogenic,drug response 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
45 PIK3CA NM_006218.4(PIK3CA):c.1637A>T (p.Gln546Leu)SNV Pathogenic/Likely pathogenic 375899 rs397517201 3:178936095-178936095 3:179218307-179218307
46 BRAF NM_004333.6(BRAF):c.1780G>C (p.Asp594His)SNV Pathogenic/Likely pathogenic 375947 rs397516896 7:140453155-140453155 7:140753355-140753355
47 IDH2 NM_002168.3(IDH2):c.515G>T (p.Arg172Met)SNV Pathogenic/Likely pathogenic 375986 rs121913503 15:90631838-90631838 15:90088606-90088606
48 IDH2 NM_002168.3(IDH2):c.515G>A (p.Arg172Lys)SNV Pathogenic/Likely pathogenic 375987 rs121913503 15:90631838-90631838 15:90088606-90088606
49 PTEN NM_000314.7(PTEN):c.518G>A (p.Arg173His)SNV Pathogenic/Likely pathogenic 376032 rs121913294 10:89711900-89711900 10:87952143-87952143
50 TP53 NM_000546.5(TP53):c.818G>C (p.Arg273Pro)SNV Pathogenic/Likely pathogenic 231060 rs28934576 17:7577120-7577120 17:7673802-7673802

Cosmic variations for Brain Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM151343377 central nervous system,brain,primitive neuroectodermal tumour-medulloblastoma,classic c.77C>G p.S26C 3:41224610-41224610 4

Copy number variations for Brain Cancer from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 112045 17 37800000 41900000 Gain Brain cancer
2 179187 8 123863081 124055936 Deletion RAF Brain cancer
3 205638 6 130400000 131300000 Deletion Brain cancer
4 233881 8 128747764 129113498 Amplification MYC Brain cancer
5 234173 8 131500000 139900000 Amplification KHDRBS3 Brain cancer
6 254105 9 51800000 140273252 Deletion Brain cancer

Expression for Brain Cancer

Search GEO for disease gene expression data for Brain Cancer.

Pathways for Brain Cancer

Pathways related to Brain Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.54 TP53 PTPN11 PIK3CA NRAS EPHB2 EGFR
2
Show member pathways
12.89 PTPN11 PTEN PIK3CA NRAS EGFR BRAF
3
Show member pathways
12.81 TP53 PTPN11 PTEN PIK3CA NRAS EGFR
4 12.76 TP53 PTEN PIK3CA NRAS EGFR BRAF
5
Show member pathways
12.73 PTPN11 PIK3CA NRAS EGFR BRAF
6
Show member pathways
12.68 TP53 PTPN11 PTEN PIK3CA NRAS EGFR
7
Show member pathways
12.67 TP53 PTPN11 PTEN PIK3CA NRAS BRAF
8
Show member pathways
12.61 TP53 SMARCB1 PTEN PIK3CA NRAS EGFR
9
Show member pathways
12.59 TP53 PTPN11 PIK3CA NRAS EGFR
10
Show member pathways
12.56 PTPN11 PTEN PIK3CA NRAS EGFR ALK
11
Show member pathways
12.51 TP53 PTEN PIK3CA NRAS EGFR BRAF
12
Show member pathways
12.48 TP53 PIK3CA NRAS EGFR BRAF
13
Show member pathways
12.43 TP53 PIK3CA NRAS EGFR
14
Show member pathways
12.4 PTPN11 PIK3CA NRAS EGFR
15
Show member pathways
12.4 TP53 PTEN PIK3CA NRAS EGFR BRAF
16
Show member pathways
12.39 TP53 PTPN11 PTEN PIK3CA
17
Show member pathways
12.38 PIK3CA NRAS EPHB2 EGFR BRAF ALK
18
Show member pathways
12.38 PTPN11 PTEN PIK3CA NRAS BRAF
19
Show member pathways
12.36 TP53 PTPN11 PTEN PIK3CA NRAS EGFR
20 12.34 TP53 PTEN PIK3CA NRAS
21
Show member pathways
12.32 PTPN11 PTEN PIK3CA NRAS
22
Show member pathways
12.27 PTPN11 PIK3CA NRAS BRAF
23 12.24 PTPN11 PIK3CA NRAS EPHB2
24
Show member pathways
12.21 TP53 PTPN11 NRAS BRAF
25 12.19 PTPN11 PTEN EGFR BRAF
26 12.19 TP53 PTEN PIK3CA NRAS MIR25 EGFR
27
Show member pathways
12.18 TP53 PIK3CA NRAS BRAF
28 12.17 TP53 PTEN PIK3CA NRAS
29 12.15 TP53 PTEN EGFR BRAF
30
Show member pathways
12.14 TP53 PTEN PIK3CA NRAS EGFR BRAF
31 12.11 TP53 PTPN11 PIK3CA NRAS EGFR BRAF
32
Show member pathways
12.09 PTPN11 PTEN PIK3CA NRAS EGFR
33
Show member pathways
12.03 TP53 PIK3CA EGFR BRAF
34 12 TP53 PTEN PIK3CA NRAS
35 11.98 TP53 PTEN PIK3CA NRAS
36
Show member pathways
11.97 PTEN PIK3CA NRAS EGFR BRAF
37 11.93 TP53 PTEN BRAF BMI1
38 11.89 PTPN11 PIK3CA NRAS EGFR
39
Show member pathways
11.8 PIK3CA NRAS BRAF
40 11.77 OLIG2 NES BMI1
41 11.71 TP53 NRAS EGFR BRAF
42 11.68 TP53 PTEN PIK3CA
43 11.59 PTPN11 PTEN PIK3CA
44 11.58 TP53 PTEN PIK3CA
45 11.48 TP53 PTEN NRAS MGMT EGFR